Genetic Stratification of Age‐Dependent Parkinson's Disease Risk by Polygenic Hazard Score
暂无分享,去创建一个
O. Andreassen | A. Dale | C. Blauwendraat | C. Fan | Z. Gan-Or | S. Bandres-Ciga | M. Tan | T. Seibert | D. Grosset | O. Frei | R. Karunamuni | L. Pihlstrøm | Z. Gan‐Or | M. Tan
[1] R. Barker,et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease , 2021, Nature Genetics.
[2] F. Collins,et al. Precision medicine in 2030—seven ways to transform healthcare , 2021, Cell.
[3] K. D. Sørensen,et al. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer , 2021, Prostate cancer and prostatic diseases.
[4] O. Andreassen,et al. Sex-dependent autosomal effects on clinical progression of Alzheimer's disease. , 2020, Brain : a journal of neurology.
[5] C. Kooperberg,et al. Improving reporting standards for polygenic scores in risk prediction studies , 2020, Nature.
[6] Jack A. Taylor,et al. African‐specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer , 2020, medRxiv.
[7] O. Andreassen,et al. Age dependence of modern clinical risk groups for localized prostate cancer—A population‐based study , 2020, Cancer.
[8] Sonja W. Scholz,et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.
[9] D. Hernandez,et al. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts , 2019, Movement disorders : official journal of the Movement Disorder Society.
[10] K. D. Sørensen,et al. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations , 2019, Nature Communications.
[11] L. Wilkins. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts , 2019, Neurology: Genetics.
[12] R. Barker,et al. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study , 2019, Brain : a journal of neurology.
[13] Ali Amin Al Olama,et al. The effect of sample size on polygenic hazard models for prostate cancer , 2019, bioRxiv.
[14] L. Sugrue,et al. What Are Polygenic Scores and Why Are They Important? , 2019, JAMA.
[15] Sonja W. Scholz,et al. Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms , 2019, Movement disorders : official journal of the Movement Disorder Society.
[16] C. Tanner,et al. Concordance for Parkinson's disease in twins: A 20‐year update , 2019, Annals of neurology.
[17] O. Andreassen,et al. A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data , 2019, Cancer Epidemiology, Biomarkers & Prevention.
[18] Yoshihiro Kokubo,et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.
[19] M. Nalls,et al. Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease , 2018, Journal of Medical Genetics.
[20] O. Andreassen,et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts , 2018, British Medical Journal.
[21] Lilah M. Besser,et al. Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score , 2017, PLoS medicine.
[22] W. Rocca,et al. Time Trends in the Incidence of Parkinson Disease. , 2016, JAMA neurology.
[23] N. Jetté,et al. The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis , 2016, Neuroepidemiology.
[24] D. Hernandez,et al. Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI) , 2016, Movement disorders : official journal of the Movement Disorder Society.
[25] M. Toft,et al. Cumulative genetic risk and age at onset in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[26] Margaret Sutherland,et al. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study , 2015, The Lancet Neurology.
[27] J. Olsen,et al. Impact of Parkinson's disease risk loci on age at onset , 2015, Movement disorders : official journal of the Movement Disorder Society.
[28] Valentina Escott-Price,et al. Genetic risk and age in Parkinson's disease: Continuum not stratum , 2015, Movement disorders : official journal of the Movement Disorder Society.
[29] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[30] R. Barker,et al. The incidence of Parkinson's disease in the North-East of England. , 2014, Age and ageing.
[31] S. Sawcer,et al. Systematic Review and UK‐Based Study of PARK2 (parkin), PINK1, PARK7 (DJ‐1) and LRRK2 in early‐onset Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[32] C. Sampaio,et al. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. , 2010, Parkinsonism & related disorders.
[33] L. Forsgren,et al. Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population‐based study , 2010, Movement disorders : official journal of the Movement Disorder Society.
[34] Gordon Johnston,et al. Statistical Models and Methods for Lifetime Data , 2003, Technometrics.